ESC Premium Access

Lipid Levels and CV Outcome with CETP Inhibition by Evacetrapib in the ACCELERATE Trial

Topic: Primary cardiovascular prevention: interventions and outcomes

Congress Session

About the speaker

Professor A Michael Lincoff

Cleveland Clinic Foundation, Cleveland (United States of America)
6 presentations
0 follower

5 more presentations in this session

The influence of blinding and un-blinding on statin related adverse events (AEs): new evidence from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Speaker: Doctor A. Gupta (London, GB)

Thumbnail

Primary prevention of patients with high LDL-cholesterol levels greater than 4.9 mmol/l: analysis from the WOSCOPS trial

Speaker: Doctor A. Vallejo-Vaz (Seville, ES)

Thumbnail

The Benefit of Adding Ezetimibe to Statin Therapy in Patients With or Without prior Coronary Artery Bypass Graft surgery in the IMPROVE-IT Trial

Speaker: Professor A. Eisen (Petah Tikva, IL)

Thumbnail

First-in-man study of a pacemaker-mediated programmable hypertension control therapy

Speaker: Professor P. Neuzil (Prague, CZ)

Thumbnail

The relationship between severe hypoglycaemic events and cardiovascular outcomes is bidirectional: novel results from TECOS

Speaker: Professor E. Standl (Munich, DE)

Thumbnail

Access the full session

Clinical Trial Update Prevention

Speakers: Professor A. Lincoff, Doctor A. Gupta, Doctor A. Vallejo-Vaz, Professor A. Eisen, Professor P. Neuzil...
Thumbnail

About the event

Image

ESC CONGRESS 2016

27 August - 31 August 2016

Sessions Presentations

This platform is supported by

logo Novo Nordisk